Market Closed -
OTC Markets
03:59:43 2024-04-26 pm EDT
|
5-day change
|
1st Jan Change
|
0.0184
USD
|
+2.22%
|
|
+6.36%
|
-95.54%
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
---|
Capitalization
1 |
144.8
|
484.7
|
150.6
|
95.95
|
54.74
|
2.835
|
Enterprise Value (EV)
1 |
144.8
|
484.7
|
134.4
|
135.3
|
54.74
|
2.835
|
P/E ratio
|
-3.68
x
|
-5.05
x
|
-1.67
x
|
-1.04
x
|
-0.72
x
|
-0.03
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
-
|
-
|
-
|
-
|
30.7
x
|
0.17
x
|
EV / Revenue
|
-
|
-
|
-
|
-
|
30.7
x
|
0.17
x
|
EV / EBITDA
|
-
|
-
|
-
|
-
|
-
|
-
|
EV / FCF
|
-
|
-8,021,047
x
|
-1,555,757
x
|
-
|
-
|
-
|
FCF Yield
|
-
|
-0%
|
-0%
|
-
|
-
|
-
|
Price to Book
|
-
|
-
|
3.47
x
|
-
|
-
|
-
|
Nbr of stocks (in thousands)
|
33,667
|
57,774
|
59,299
|
74,381
|
132,639
|
154,051
|
Reference price
2 |
4.300
|
8.390
|
2.540
|
1.290
|
0.4127
|
0.0184
|
Announcement Date
|
2/25/20
|
3/9/21
|
3/15/22
|
3/27/23
|
3/27/24
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
---|
Net sales
1 |
-
|
-
|
-
|
-
|
1.784
|
16.79
|
EBITDA
|
-
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
-48.24
|
-62.3
|
-87.17
|
-74.99
|
-73.04
|
-66.08
|
Operating Margin
|
-
|
-
|
-
|
-
|
-4,094.06%
|
-393.53%
|
Earnings before Tax (EBT)
1 |
-34.42
|
-72.7
|
-89.79
|
-79.38
|
-63
|
-70.08
|
Net income
1 |
-34.35
|
-72.7
|
-89.79
|
-79.38
|
-63
|
-71.64
|
Net margin
|
-
|
-
|
-
|
-
|
-3,531.17%
|
-426.65%
|
EPS
2 |
-1.170
|
-1.660
|
-1.520
|
-1.240
|
-0.5700
|
-0.5700
|
Free Cash Flow
|
-
|
-60.43
|
-96.81
|
-
|
-
|
-
|
FCF margin
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
2/25/20
|
3/9/21
|
3/15/22
|
3/27/23
|
3/27/24
|
-
|
Fiscal Period: December |
2021 Q3
|
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
---|
Net sales
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
0.673
|
1.111
|
4.435
|
4.628
|
5.013
|
5.206
|
EBITDA
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
-23.14
|
-22.32
|
-19.32
|
-18.05
|
-17.06
|
-20.56
|
-19.58
|
-18.8
|
-18.08
|
-16.62
|
-15.95
|
-16.3
|
-16.99
|
-16.84
|
Operating Margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-2,687.22%
|
-1,495.77%
|
-359.68%
|
-352.16%
|
-338.9%
|
-323.38%
|
Earnings before Tax (EBT)
1 |
-19.63
|
-30.83
|
-20.22
|
-18.55
|
-17.8
|
-22.8
|
-20.96
|
-31.68
|
-1.519
|
-8.841
|
-16.95
|
-17.3
|
-17.99
|
-17.84
|
Net income
1 |
-19.63
|
-30.83
|
-20.22
|
-18.55
|
-17.8
|
-22.8
|
-20.96
|
-31.68
|
-1.519
|
-8.841
|
-16.95
|
-17.3
|
-17.99
|
-17.84
|
Net margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-225.71%
|
-795.77%
|
-382.23%
|
-373.77%
|
-358.85%
|
-342.59%
|
EPS
2 |
-0.3300
|
-0.5200
|
-0.3400
|
-0.3100
|
-0.2900
|
-0.2900
|
-0.2700
|
-0.3100
|
-0.0100
|
-0.0400
|
-0.1400
|
-0.1500
|
-0.1500
|
-0.1500
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
11/15/21
|
3/15/22
|
5/10/22
|
8/15/22
|
11/14/22
|
3/27/23
|
5/15/23
|
8/14/23
|
11/14/23
|
3/27/24
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
---|
Net Debt
|
-
|
-
|
-
|
39.3
|
-
|
-
|
Net Cash position
|
-
|
-
|
16.2
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
|
-
|
-60.4
|
-96.8
|
-
|
-
|
-
|
ROE (net income / shareholders' equity)
|
-
|
-
|
-
|
-
|
-
|
-
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-
|
-
|
-
|
-
|
Assets
1 |
-
|
-
|
-
|
-
|
-
|
-
|
Book Value Per Share
|
-
|
-
|
0.7300
|
-
|
-
|
-
|
Cash Flow per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex
|
-
|
-
|
15.1
|
-
|
-
|
-
|
Capex / Sales
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
2/25/20
|
3/9/21
|
3/15/22
|
3/27/23
|
3/27/24
|
-
|
Last Close Price
0.0184
USD Average target price
6
USD Spread / Average Target +32,508.70% Consensus |
1st Jan change
|
Capi.
|
---|
| -95.54% | 2.83M | | -2.31% | 103B | | +0.56% | 95.28B | | +1.69% | 22.15B | | -17.37% | 21.02B | | -9.30% | 18.15B | | -41.01% | 16.74B | | -14.85% | 16.05B | | +3.21% | 13.68B | | +33.54% | 12.17B |
Bio Therapeutic Drugs
|